RNS Number : 7571F
NetScientific PLC
16 November 2015
 



 NetScientific PLC

("NetScientific" or the "Group")

 

 

London, UK - 16 November 2015: NetScientific PLC (AIM: NSCI.L), a transatlantic biomedical healthcare group, announces that it will today apply to admit, in total, 54,167 ordinary shares of 5p each to trading on AIM. Admission is expected on 20 November 2015 and these shares will rank pari passu with the existing ordinary shares in issue.

 

These shares are being subscribed for by a small number of employees who expressed an interest to the Board in acquiring shares in the Company, but who were unable to as part of the recent fundraising as they were not existing shareholders in NetScientific. None of these employees are directors of the Company.  The subscription price is equal to that of the recent fundraising, announced on 1 October 2015, being 120 pence per ordinary share

 

On Admission, the Company's issued share capital will comprise 51,075,695 Ordinary Shares, none of which will be held in treasury. This figure may be used by shareholders and other investors as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure and Transparency Rules

 

 -Ends-

 

 

Contact Details

 

NetScientific plc

Tel: +44 (0)20 3514 1800

François Martelet, CEO

    

Peter Thoms, CFO

 

 

 

Investec Bank plc (NOMAD & Broker)

Gary Clarence

Daniel Adams

Tel: +44 (0)20 7597 4000

 

 

Instinctif Partners

Melanie Toyne-Sewell

Jayne Crook

Rosanna Forrest

Tel: +44 (0)20 7457 2020

netscientific@instinctif.com

       

 

 

 

 

 

 

 

 

About NetScientific

NetScientific is a transatlantic biomedical and healthcare technology group with a differentiated investment strategy focused solely on digital health, diagnostics and therapeutics. The Group's objective is to source, fund and commercialise companies that significantly improve the lives of people with chronic diseases.

For more information, please visit the website at www.netscientific.net.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEPKPDQABDDADD